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Several recent benchmarking efforts provide reference datasets and samples to improve genome
sequencing and calling of germline and somatic mutations.Large-scale studies and high-stakes
applications, such as clinical decision
making, require careful benchmarking of
technologies. Here, we highlight recent
advances in benchmarking approaches
for genome sequencing and related bioin-
formatics methods. In this issue of Cell
Systems, Griffith et al. describe the ultra-
high-depth sequencing of whole ge-
nomes and exomes from normal, primary
cancer and relapse tissue from a patient
with acute myeloid leukemia (Griffith
et al., 2015). The raw data, along with a
set of validated somatic variant calls—
one of the most comprehensive individual
cancer genome-sequence datasets to
date—provide a valuable resource that
can be used to benchmark somatic muta-
tion calling. In addition, these results
complement ongoing somatic mutation-
calling ‘‘challenges’’ and efforts reported
at a recent public workshop from the
Genome in a Bottle Consortium on stan-
dardizing and benchmarking next-gener-
ation sequencing.
One approach for evaluating the perfor-
mance of a genome-sequencing and
variant-calling method is to apply it to a
reference DNA sample for which the
sequence and variants are known. This
is the strategy taken by the National Insti-
tute of Standards and Technology (NIST),
which in May 2015 released the first well-
characterized whole-genome reference
material (NIST RM8398) (Nature, 2015).
The reference material is based on the
NA12878 DNA from the Coriell Cell Line
Repository. As immortalized cell lines
can be used, it is relatively straightforward
to create reference materials for germline
genomes.
In contrast, creating cancer reference
samples and calling somatic (non-germ-
line) mutations from cancer samples is
more challenging. Particular somatic176 Cell Systems 1, September 23, 2015 ª20mutations occur in only a small proportion
of the measured cells because tumor
samples often include a significant pro-
portion of normal cells, and a single tumor
itself can contain clones with different
variants. Very high coverage is often
needed to detect these somatic variants,
and even with high coverage, it is difficult
to distinguish true somatic variants from
systematic errors.
Griffith et al. address these challenges
by sequencing several samples from a
single patient with acute myeloid leuke-
mia. They use whole-genome sequencing
and multiple high-coverage targeted
sequencing methods (Table 1 of their
paper). In addition, the authors applied
several bioinformatics pipelines to ex-
plore the variability among methods.
This work yielded a number of valuable
resources. The authors manually re-
viewed a subset of variants to create a
‘‘platinum list’’ of variants that can be
used for benchmarking somatic mutation
callers. Table 2 of their paper summarizes
key findings and recommendations. The
authors also provide a website to explore
the data from this patient sample (http://
aml31.genome.wustl.edu/). Although
users need permission to download the
data from dbGaP, the authors have tried
to make this as painless as possible.
While these data are limited to a snapshot
of current commonly used technologies,
bioinformaticians may find these data
useful for developing and optimizing
somatic mutation-calling methods.
In particular, improved methods are
needed to characterize certain types of
difficult-to-call mutations in this genome
and others. In this respect, the work of
Griffith et al. highlights challenges similar
to those recently identified by the steering
committee of the Genome in a Bottle
Consortium.15 Elsevier Inc.Genome in a Bottle
On August 27 and 28, 2015, the National
Institute of Standards and Technology
convened the sixth public workshop of
the Genome in a Bottle Consortium
(GIAB), with more than 150 public,
commercial, and academic stakeholders.
The consortium was formed by the
National Institute of Standards and
Technology in 2012 to develop well-char-
acterized samples that can be used to
evaluate DNA-sequencing measurement
performance. Recently reported pilot
results examined library preparation,
sequencing, and bioinformatics (Zook
et al., 2014).
The sixth workshop began with the
release of extensive data from two
mother-father-son trios from the Personal
Genome Project that were generated by
the consortium since the last workshop.
These data are from 11 technologies and
included the first public trio sequencing
using long-read technology (Table 1).
GIAB makes all data public immediately
so that anyone can analyze and publish
about them. The consortium has formed
a team to coordinate analyses, with 15
groups presenting at the workshop and
additional groups developing analyses.
A highlight of this workshop was the
progress toward developing benchmark
variant calls for previously inaccessible
regions (e.g., repetitive regions) and
variant types (e.g., structural variants) in
the genome. The initially released bench-
mark calls for the pilot sample (Zook et al.,
2014) were limited to small variants in
about 77% of the genome (with 23% of
the genome, including 23% of the clini-
cally relevant genome, inaccessible). To
advance beyond this, at the workshop,
15 GIAB members presented algorithms
to take advantage of long reads, ‘‘read
clouds,’’ and other data from Table 1 to
Table 1. Summary of Data Generated by the Genome in a Bottle Consortium for an Ashkenazim Trio and by Griffith et al. for a Normal
Sample, Primary Tumor Sample, and Relapse Tumor Sample
Study Data Type Technologies Coverage
GIAB Paired-end short reads Illumina WGS, Complete Genomics WGS,
Ion Torrent exome, SOLiD WGS
WGS: 50–3003; exome: 10003
GIAB Long mate-pair Illumina WGS 153
GIAB ‘‘Read clouds’’ Moleculo, 103, LFR 20–1003
GIAB Long reads Pacific Biosciences, Oxford Nanopore <1–703
GIAB Optical mapping BioNano Genomics 50–1003
Griffith et al. Paired-end short reads Illumina WGS, exome WGS: 38–3123; exome: 251–4333
Griffith et al. Targeted sequencing Illumina, Ion Torrent 43–13,7253
Griffith et al. RNA-seq Illumina 32–542 Gbp
For additional details, see Figure 1 and Table 1 in (Griffith et al., 2015). Certain commercial equipment, instruments, or materials are identified in this
paper only to specify the experimental procedure adequately. Such identification is not intended to imply recommendation or endorsement by the
National Institute of Standards and Technology, nor is it intended to imply that the materials or equipment identified are necessarily the best available
for the purpose. WGS, whole-genome sequencing; LFR, long fragment read.
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Previewsdiscover structural variants, characterize
difficult regions of the genome, and
phase variants at long distances. These
methods to generate calls, along with
methods to integrate calls to form high-
confidence structural variants (English
et al., 2015), will advance our understand-
ing of difficult variants and difficult regions
in the next year.
The Genome in a Bottle Consortium is
also considering benchmark samples for
somatic mutation calling. There are three
relevant commercial products available
that are based on candidate GIAB Refer-
ence Materials, including formalin-fixed
and paraffin-embedded cell lines and
cell line DNA with synthetic DNA spike-
ins that simulate somatic mutations at
different allele fractions. These products
are possible because the genomes
selected by GIAB are those of individuals
from the Personal Genome Project who
have consented to permit commercial-
derived products from those genomes
(Ball et al., 2012).
In a parallel effort, earlier this year,
the International Cancer Genome Con-
sortium-The Cancer Genome Atlas
DREAM Somatic Mutation Calling Chal-
lenge published results from a com-
petition using modified real data to
test somatic mutation-calling algorithms
(Ewing et al., 2015). They found common
sequencing error modes that caused
false positives from algorithms. They
also found that using an ensemble ofmultiple algorithms produced the best
results. The Challenge provides a public
platform to evaluate new submissions as
algorithms continue to be refined and
new algorithms are developed. In addi-
tion, results from a new challenge with
real tumor data are expected to be
announced in Fall 2015.
Even with good benchmarks, standard
definitions for performance metrics and
standard sophisticated variant compari-
son pipelines are essential for users of
reference materials and reference data
to compare performance. In partnership
with GIAB, the Global Alliance for Geno-
mics and Health formed a Benchmarking
Team to develop standard definitions
and tools for benchmarking variant calls.
The team has developed several tools
for variant comparisons and is currently
reconciling reporting to get the same
standardized performance metrics from
each tool.
Overall, what is still needed are broadly
consented cancer samples that will allow
public dissemination of DNA reference
material as well as public data from these
genomes. In addition to the spike-ins for
a small number of mutations discussed
above, GIAB has discussed possible
ways to address this need, but none
are ideal. Cancer samples and genomes
are diverse, with a wide spectrum of
morphology, cellularity, heterogeneity,
number of mutations, types of mutations,
and ploidy, so a limited set of samples isCell Systems 1, Seunlikely to meet all needs. Gaining confi-
dence in results from tumor sequencing
will likely take a variety of types of refer-
encematerials and reference data, poten-
tially including samples and data from
multiple tumor types, tumor-normal cell
line pairs, normal cell line mixtures, and
real data modified in silico. The works of
the DREAM Challenge and Griffith et al.
are important steps toward bench-
marking cancer genome sequencing,
and they provide a great foundation for
future work, including that within GIAB.
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